Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$100,000.00

The role of developing group 2 innate lymphoid cell perivascular niches in early life lung immunity

EF 2018-19

Résumé
Allergic asthma is the leading chronic disease in children, defined by recurrent episodes of shortness of breath, wheezing, and in some cases catastrophic respiratory failure. Although medications can treat asthma symptoms, it remains an incurable and debilitating disease. Early-life exposure to allergens or respiratory viruses are common triggers, and childhood asthma frequently persists into adulthood, indicating that early-life 'immune education' can shape adult immunity and asthma susceptibility. A new type of immune cell called group 2 innate lymphoid cells (ILC2s) have been recently identified as critical drivers of allergic inflammation, including allergic asthma. Interestingly, ILC2s are abundant in healthy neonatal mouse lungs, and the majority of lung ILC2s in adults are derived from this neonatal period. Preliminary results show that ILC2s remain in conserved lung "niches" throughout life and are regulated by surrounding stromal cells. How these niches develop after birth, and whether this contributes to age-specific sensitivity to allergens and viruses, has yet to be elucidated. This project aims to determine what signals are required for the development of these ILC2 niches, how exposure to allergens and common respiratory viruses alter the niche development and function, and whether this may contribute to the initiation of asthma in children. The obtained results will contribute to our understanding of early immune education and may lead to potential therapeutics for the prevention of asthma.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
396369
Name
Steer Catherine
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The role of developing group 2 innate lymphoid cell perivascular niches in early life lung immunity
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
3d Imaging; Allergy; Asthma; Group 2 Innate Lymphoid Cells; Neonates; Type 2 Immunity
Abstract
Allergic asthma is the leading chronic disease in children, defined by recurrent episodes of shortness of breath, wheezing, and in some cases catastrophic respiratory failure. Although medications can treat asthma symptoms, it remains an incurable and debilitating disease. Early-life exposure to allergens or respiratory viruses are common triggers, and childhood asthma frequently persists into adulthood, indicating that early-life 'immune education' can shape adult immunity and asthma susceptibility. A new type of immune cell called group 2 innate lymphoid cells (ILC2s) have been recently identified as critical drivers of allergic inflammation, including allergic asthma. Interestingly, ILC2s are abundant in healthy neonatal mouse lungs, and the majority of lung ILC2s in adults are derived from this neonatal period. Preliminary results show that ILC2s remain in conserved lung "niches" throughout life and are regulated by surrounding stromal cells. How these niches develop after birth, and whether this contributes to age-specific sensitivity to allergens and viruses, has yet to be elucidated. This project aims to determine what signals are required for the development of these ILC2 niches, how exposure to allergens and common respiratory viruses alter the niche development and function, and whether this may contribute to the initiation of asthma in children. The obtained results will contribute to our understanding of early immune education and may lead to potential therapeutics for the prevention of asthma.
Competitiondate
201811
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Steer, Catherine
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~